The global Minimal Residual Disease (MRD) market is booming, projected to reach $1.9 billion by 2025 and grow at a CAGR of 12.88% through 2033. Driven by advancements in PCR, FISH, and NGS technologies, this market offers lucrative opportunities for key players like Novartis and Amgen. Learn more about market trends, regional analysis, and key drivers impacting MRD testing.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.